Arcutis Biotherapeutics (ARQT) Gross Profit (2022 - 2026)

Arcutis Biotherapeutics' Gross Profit history runs 5 years deep, the most recent figure standing at $95.6 million for Q1 2026.

• In Q1 2026, Gross Profit rose 73.79% year-over-year to $95.6 million; the TTM figure through Mar 2026 stood at $378.0 million (up 105.29% YoY), while the FY2025 annual figure was $339.4 million, up 130.22% from the prior year.
• Gross Profit for Q1 2026 stood at $95.6 million, down from $117.8 million in the prior quarter.
• The five-year high for Gross Profit was $117.8 million in Q4 2025, with the low at $456000.0 in Q3 2022.
• The 5-year median for Gross Profit is $39.3 million (2024), against an average of $44.5 million.
• The sharpest annual moves came in 2023 and 2024: Gross Profit soared 7998.03% in 2023, then grew 6.3% in 2024.
• Arcutis Biotherapeutics' Gross Profit stood at $2.5 million in 2022, then soared by 1584.17% to $41.7 million in 2023, then jumped by 49.77% to $62.5 million in 2024, then soared by 88.64% to $117.8 million in 2025, then dropped by 18.84% to $95.6 million in 2026.
• Business Quant data shows ARQT's Gross Profit at $95.6 million in Q1 2026, $117.8 million in Q4 2025, and $90.5 million in Q3 2025.